ldtЛучевая диагностика и терапияDiagnostic radiology and radiotherapy2079-5343Baltic Medical Education Center10.22328/2079-5343-2023-14-2-7-14ldt-874Research ArticleРЕДАКЦИОННАЯ СТАТЬЯEDITORIALРанняя диагностика агрессивных форм рака: альянс специалистов, технологий и искусственного интеллектаEarly diagnostics of aggressive cancers: alliance of physicians, technologies and artificial intelligencehttps://orcid.org/0000-0002-7721-634XРумянцевП. О.RumiantsevP. O.

Румянцев Павел Олегович — доктор медицинских наук, профессор, заместитель главного врача

191186, Санкт-Петербург, Малая Конюшенная, д. 8

Pavel O. Rumiantsev — Dr. of Sci. (Med.), professor, Deputy Chief doctor 

8, Malaya Konyushennaya, St. Petersburg, 191186

pavelrum@gmail.comГруппа клиник «Мой медицинский центр»РоссияGroup of clinics «My Medical Center»Russian Federation202305072023142714Copyright © Румянцев П.О., 20232023Румянцев П.О.Rumiantsev P.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://radiag.bmoc-spb.ru/jour/article/view/874

Одной из наиболее распространенных причин снижения продолжительности и качества жизни среди населения являются злокачественные новообразования (ЗНО), обладающие высокой биологической агрессивностью. Повысить выявляемость агрессивных ЗНО на ранней, потенциально излечимой, стадии опухоли можно только посредством специализированной диспансеризации групп высокого риска среди населения, с учетом пола, возраста, наследственной предрасположенности, влияния канцерогенных и иных факторов. В этой связи нарастает необходимость междисциплинарной коммуникации, улучшения диагностических и терапевтических технологий, альянса врачей, биологов, химиков, физиков, инженеров и математиков для симбиоза в развитии биотехнологий, алгоритмов машинного обучения, пополнения доказательной базы и совершенствования вспомогательных ресурсов искусственного интеллекта. Статья посвящена анализу стоящих перед современной биомедициной задач и путей их решения.

One of the most common threats to reducing the duration and quality of life among the population is malignant tumors, which have high biological aggressiveness. It is possible to increase the detection of aggressive tumors at an early, potentially curable, stage of the tumor only through specialized medical examination of high-risk groups among the population, taking into account gender, age, hereditary predisposition, the influence of carcinogenic and other factors. In this regard, there is a growing need for interdisciplinary communication, improvement of diagnostic and therapeutic technologies, an alliance of doctors, biologists, chemists, physicists, engineers and mathematicians for symbiosis in the development of biotechnologies, machine learning algorithms, replenishment of the evidence base and improvement of auxiliary resources of artificial intelligence. The article is devoted to the analysis of the challenges facing modern biomedicine and ways to solve them.

искусственный интеллектракгруппы рискабиомедицинапроактивная диагностикаartificial intelligencecancerrisk groupsbiomedicineproactive diagnosticsReferencesWelch G. Cancer Screening — The Good, the Bad, and the Ugly // JAMA Surg. 2022. Jun. 1. Vol. 157, No. 6. Р. 467–468. doi: 10.1001/jamasurg.2022.0669.Welch G. Cancer Screening — The Good, the Bad, and the Ugly // JAMA Surg. 2022. Jun. 1. Vol. 157, No. 6. Р. 467–468. doi: 10.1001/jamasurg.2022.0669.Marmot M.G., Altman D.G., Cameron D.A. et al. The benefits and harms of breast cancer screening: An independent review // Br. J. Cancer. 2013. Vol. 108, No. 11. Р. 2205–2240. doi: 10.1038/bjc.2013.177.Marmot M.G., Altman D.G., Cameron D.A. et al. The benefits and harms of breast cancer screening: An independent review // Br. J. Cancer. 2013. Vol. 108, No. 11. Р. 2205–2240. doi: 10.1038/bjc.2013.177.Kuchenbaecker K.B., Hopper J.L., Barnes D.R. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers // JAMA — Journal of the American Medical Association. 2017. Vol. 317, No. 23. Р. 2402–2416. doi: 10.1001/jama.2017.7112.Kuchenbaecker K.B., Hopper J.L., Barnes D.R. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers // JAMA — Journal of the American Medical Association. 2017. Vol. 317, No. 23. Р. 2402–2416. doi: 10.1001/jama.2017.7112.Ilic D., Neuberger M.M., Djulbegovic M., Dahm P. Screening for prostate cancer // Cochrane Database of Systematic Reviews. 2013. Vol. 2013, No. 1. doi: 10.1002/14651858.CD004720.pub3.Ilic D., Neuberger M.M., Djulbegovic M., Dahm P. Screening for prostate cancer // Cochrane Database of Systematic Reviews. 2013. Vol. 2013, No. 1. doi: 10.1002/14651858.CD004720.pub3.Gøtzsche P.C., Jørgensen K.J. Screening for breast cancer with mammography // Cochrane Database of Systematic Reviews. 2013. Vol. 2013, No. 6. doi: 10.1002/14651858.CD001877.pub5.Gøtzsche P.C., Jørgensen K.J. Screening for breast cancer with mammography // Cochrane Database of Systematic Reviews. 2013. Vol. 2013, No. 6. doi: 10.1002/14651858.CD001877.pub5.Welch H.G., Prorok P.C., O’Malley A.J., Kramer B.S. Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness // New England Journal of Medicine. 2016. Vol. 375, No. 15. Р. 1438–1447. doi: 10.1056/nejmoa1600249.Welch H.G., Prorok P.C., O’Malley A.J., Kramer B.S. Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness // New England Journal of Medicine. 2016. Vol. 375, No. 15. Р. 1438–1447. doi: 10.1056/nejmoa1600249.McGeoch L., Saunders C.L., Griffin S.J. et al. Risk prediction models for colorectal cancer incorporating common genetic variants: A systematic review // Cancer Epidemiology Biomarkers and Prevention. 2019. Vol. 28, No. 10. Р. 1580–1593. doi: 10.1158/1055-9965.EPI-19-0059.McGeoch L., Saunders C.L., Griffin S.J. et al. Risk prediction models for colorectal cancer incorporating common genetic variants: A systematic review // Cancer Epidemiology Biomarkers and Prevention. 2019. Vol. 28, No. 10. Р. 1580–1593. doi: 10.1158/1055-9965.EPI-19-0059.Hugosson J., Roobol M.J., Månsson M. et al. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer (Figure presented) // Eur. Urol. 2019. Vol. 76, No. 1. Р. 43–51. doi: 10.1016/j.eururo.2019.02.009.Hugosson J., Roobol M.J., Månsson M. et al. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer (Figure presented) // Eur. Urol. 2019. Vol. 76, No. 1. Р. 43–51. doi: 10.1016/j.eururo.2019.02.009.Bucchi L., Mancini S., Baldacchini F. et al. How a faecal immunochemical test screening programme changes annual colorectal cancer incidence rates: an Italian intention-to-screen study // Br. J. Cancer. 2022. Vol. 127, No. 3. Р. 541–548. doi: 10.1038/s41416-022-01813-7.Bucchi L., Mancini S., Baldacchini F. et al. How a faecal immunochemical test screening programme changes annual colorectal cancer incidence rates: an Italian intention-to-screen study // Br. J. Cancer. 2022. Vol. 127, No. 3. Р. 541–548. doi: 10.1038/s41416-022-01813-7.Clift A.K., Dodwell D., Lord S. et al. The current status of risk-stratified breast screening // Br. J. Cancer. 2022. Vol. 126, No. 4. Р. 533–550. doi: 10.1038/s41416021-01550-3.Clift A.K., Dodwell D., Lord S. et al. The current status of risk-stratified breast screening // Br. J. Cancer. 2022. Vol. 126, No. 4. Р. 533–550. doi: 10.1038/s41416021-01550-3.Menon U., Gentry-Maharaj A., Burnell M. et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial // The Lancet. 2021. Vol. 397, No. 10290. Р. 2182–2193. doi: 10.1016/S0140-6736(21)00731-5.Menon U., Gentry-Maharaj A., Burnell M. et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial // The Lancet. 2021. Vol. 397, No. 10290. Р. 2182–2193. doi: 10.1016/S0140-6736(21)00731-5.Pashayan N., Morris S., Gilbert F.J., Pharoah P.D.P. Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer A Life-Table Model // JAMA Oncol. 2018. Vol. 4, No. 11. Р. 1504–1510. doi: 10.1001/jamaoncol.2018.1901.Pashayan N., Morris S., Gilbert F.J., Pharoah P.D.P. Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer A Life-Table Model // JAMA Oncol. 2018. Vol. 4, No. 11. Р. 1504–1510. doi: 10.1001/jamaoncol.2018.1901.Srivastava S., Koay E.J., Borowsky A.D. et al. Cancer overdiagnosis: a biological challenge and clinical dilemma // Nat. Rev. Cancer. 2019. Vol. 19, No. 6. Р. 349– 358. doi: 10.1038/s41568-019-0142-8.Srivastava S., Koay E.J., Borowsky A.D. et al. Cancer overdiagnosis: a biological challenge and clinical dilemma // Nat. Rev. Cancer. 2019. Vol. 19, No. 6. Р. 349– 358. doi: 10.1038/s41568-019-0142-8.Alpert P.F. New Evidence for the Benefit of Prostate-specific Antigen Screening: Data From 400,887 Kaiser Permanente Patients // Urology. 2018. Vol. 118. Р. 119– 126. doi: 10.1016/j.urology.2018.02.049.Alpert P.F. New Evidence for the Benefit of Prostate-specific Antigen Screening: Data From 400,887 Kaiser Permanente Patients // Urology. 2018. Vol. 118. Р. 119– 126. doi: 10.1016/j.urology.2018.02.049.Bond M., Pavey T., Welch K. et al. Systematic review of the psychological consequences of false-positive screening mammograms // Health Technol Assess (Rockv). 2013. Vol. 17, No. 13. Р. 1–86. doi: 10.3310/hta17130.Bond M., Pavey T., Welch K. et al. Systematic review of the psychological consequences of false-positive screening mammograms // Health Technol Assess (Rockv). 2013. Vol. 17, No. 13. Р. 1–86. doi: 10.3310/hta17130.Sarkeala T., Färkkilä M., Anttila A. et al. Piloting gender-oriented colorectal cancer screening with a faecal immunochemical test: Population-based registry study from Finland // BMJ Open. 2021. Vol. 11, No. 2. doi: 10.1136/bmjopen-2020-046667.Sarkeala T., Färkkilä M., Anttila A. et al. Piloting gender-oriented colorectal cancer screening with a faecal immunochemical test: Population-based registry study from Finland // BMJ Open. 2021. Vol. 11, No. 2. doi: 10.1136/bmjopen-2020-046667.Hewitson P., Glasziou P., Irwig L. et al. Screening for colorectal cancer using the faecal occult blood test, Hemoccult // Cochrane Database of Systematic Reviews. 2007. No. 1. doi: 10.1002/14651858.CD001216.pub2.Hewitson P., Glasziou P., Irwig L. et al. Screening for colorectal cancer using the faecal occult blood test, Hemoccult // Cochrane Database of Systematic Reviews. 2007. No. 1. doi: 10.1002/14651858.CD001216.pub2.Adeyemo A., Balaconis M.K., Darnes D.R. et al. Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps // Nat. Med. 2021. Vol. 27, No. 11. Р. 1876–1884. doi: 10.1038/s41591-021-01549-6.Adeyemo A., Balaconis M.K., Darnes D.R. et al. Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps // Nat. Med. 2021. Vol. 27, No. 11. Р. 1876–1884. doi: 10.1038/s41591-021-01549-6.Wand H., Lambert S.A., Tamburro C. et al. Improving reporting standards for polygenic scores in risk prediction studies // Nature. 2021. Vol. 591, No. 7849. Р. 211– 219. doi: 10.1038/s41586-021-03243-6.Wand H., Lambert S.A., Tamburro C. et al. Improving reporting standards for polygenic scores in risk prediction studies // Nature. 2021. Vol. 591, No. 7849. Р. 211– 219. doi: 10.1038/s41586-021-03243-6.Lenaerts L., Brison N., Maggen C. et al. Comprehensive genome-wide analysis of routine non-invasive test data allows cancer prediction: A single-center retrospective analysis of over 85,000 pregnancies // EClinical. Medicine. 2021. Vol. 35. doi: 10.1016/j.eclinm.2021.100856.Lenaerts L., Brison N., Maggen C. et al. Comprehensive genome-wide analysis of routine non-invasive test data allows cancer prediction: A single-center retrospective analysis of over 85,000 pregnancies // EClinical. Medicine. 2021. Vol. 35. doi: 10.1016/j.eclinm.2021.100856.Nieuwenburg S.A.V., Mommersteeg M.C., Wolters L.M.M. et al. Accuracy of H. pylori fecal antigen test using fecal immunochemical test (FIT) // Gastric Cancer. 2022. Vol. 25, No. 2. Р. 375–381. doi: 10.1007/s10120-021-01264-8.Nieuwenburg S.A.V., Mommersteeg M.C., Wolters L.M.M. et al. Accuracy of H. pylori fecal antigen test using fecal immunochemical test (FIT) // Gastric Cancer. 2022. Vol. 25, No. 2. Р. 375–381. doi: 10.1007/s10120-021-01264-8.Newman A.M., Bratman S.V., To J. et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage // Nat. Med. 2014. Vol. 20, No. 5. Р. 548–554. doi: 10.1038/nm.3519.Newman A.M., Bratman S.V., To J. et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage // Nat. Med. 2014. Vol. 20, No. 5. Р. 548–554. doi: 10.1038/nm.3519.Abou-Elkacem L., Bachawal S.V., Willmann J.K. Ultrasound molecular imaging: Moving toward clinical translation // Eur. J. Radiol. 2015. Vol. 84, No. 9. Р. 1685– 1693. doi: 10.1016/j.ejrad.2015.03.016.Abou-Elkacem L., Bachawal S.V., Willmann J.K. Ultrasound molecular imaging: Moving toward clinical translation // Eur. J. Radiol. 2015. Vol. 84, No. 9. Р. 1685– 1693. doi: 10.1016/j.ejrad.2015.03.016.Eklund M., Jäderling F., Discacciati A. et al. MRI-Targeted or Standard Biopsy in Prostate Cancer Screening // New England Journal of Medicine. 2021. Vol. 385, No. 10. Р. 908–920. doi: 10.1056/nejmoa2100852.Eklund M., Jäderling F., Discacciati A. et al. MRI-Targeted or Standard Biopsy in Prostate Cancer Screening // New England Journal of Medicine. 2021. Vol. 385, No. 10. Р. 908–920. doi: 10.1056/nejmoa2100852.Wang Y., De Leon A.C., Perera R. et al. Molecular imaging of orthotopic prostate cancer with nanobubble ultrasound contrast agents targeted to PSMA // Sci. Rep. 2021. Vol. 11, No. 1. doi: 10.1038/s41598-021-84072-5.Wang Y., De Leon A.C., Perera R. et al. Molecular imaging of orthotopic prostate cancer with nanobubble ultrasound contrast agents targeted to PSMA // Sci. Rep. 2021. Vol. 11, No. 1. doi: 10.1038/s41598-021-84072-5.Falcaro M., Castañon A., Ndlela B. et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study // The Lancet. 2021. Vol. 398, No. 10316. Р. 2084–2092. doi: 10.1016/S0140-6736(21)02178-4.Falcaro M., Castañon A., Ndlela B. et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study // The Lancet. 2021. Vol. 398, No. 10316. Р. 2084–2092. doi: 10.1016/S0140-6736(21)02178-4.Elemento O., Leslie C., Lundin J., Tourassi G. Artificial intelligence in cancer research, diagnosis and therapy. Nat Rev Cancer. 2021. Vol. 21, No. 12):747–752. doi: 10.1038/s41568-021-00399-1.Elemento O., Leslie C., Lundin J., Tourassi G. Artificial intelligence in cancer research, diagnosis and therapy. Nat Rev Cancer. 2021. Vol. 21, No. 12):747–752. doi: 10.1038/s41568-021-00399-1.

The authors declare that there are no conflicts of interest present.